Evidence map›Paper›PMID 41234639›Full record

ArticleIranian journal of microbiology2025

Assessing the beneficial effect of

Manizheh Hajizadeh Varzeghan, Gholamreza Zarrini, Farzam Sheikhzadeh Hesari, Mohammad Hossein Modarressi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Manizheh Hajizadeh VarzeghanDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Gholamreza ZarriniDepartment of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Farzam Sheikhzadeh HesariDepartment of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Mohammad Hossein ModarressiDepartment of Medical Genetics, School of Medicine, Tehran University of Medicine Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Probiotics are effective in improving inflammatory bowel disease (IBD). This study assessed the effect of mesalazine and two candidate probiotics on the improvement of acetic acid (AA)-induced colitis model. Materials and Methods: Results: The results showed that the probiotic bacteria reduced inflammation (P<0.05), extent (P<0.01), crypt abscesses (P<0.01), edema (P<0.05), inflammatory cell infiltration (P<0.5), and increased mucosa (P<0.001) in rats. Mesalazine administration in animals with colitis did not have a significant effect. Administration of probiotics in both CLP and CLPM groups reduced extent, crypt abscesses, edema, and inflammatory cell infiltration and showed an important role in the down-regulation of consolidation of pro-inflammatory factors (TNFα, IL-6, and IL-17), as well as up-regulation of anti-inflammatory factors such as IL-10. Conclusion:

Indexed as

Inflammatory bowel diseaseInflammatory cytokinesLactic acid bacteriaProbiotics

Identifiers

PMID41234639
PMCPMC12607245

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.